A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
A separate 2026 not-peer-reviewed medRxiv controlled exposure preprint reported symptomatic pertussis after deliberate bacterial inoculation; results are provisional and not independent of that preprint's own dose-escalation subgroup.